RxDoctor Payments Data

Chelsey Farless, APRN

Family · Princeton, KYNPI 1891171724

Payments from drug & device makers

$2,373in general payments, 2019–2025

Across 166 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$744
  • Novo Nordisk$450
  • Axsome Therapeutics, Inc.$191
  • Otsuka America Pharmaceutical, Inc.$185
  • Amgen$168
  • Novartis$147
  • plus $489 from 16 others

What the payments were for

  • Food & beverage$2,35999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,373 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,053
Medicare patients
55
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$75,916
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,332
FarxigaDapagliflozin Propanediol25$16,244
JanuviaSitagliptin Phosphate20$15,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,751
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$4,891
SymbicortBudesonide/Formoterol Fumarate11$3,929
Albuterol Sulfate HfaAlbuterol Sulfate65$2,041
Ventolin HfaAlbuterol Sulfate24$1,675
Gabapentin128$1,437
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$1,205
Atorvastatin Calcium181$1,047
Humulin RInsulin Regular, Human13$1,005
Duloxetine Hcl57$893
Baclofen14$878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$450$75,91669 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$28$36,50555 claims
GSKTrelegy Ellipta$37$9,75112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Princeton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →